Logos Global Management LP - Q1 2023 holdings

$699 Million is the total value of Logos Global Management LP's 43 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 52.5% .

 Value Shares↓ Weighting
APLS SellAPELLIS PHARMACEUTICALS INC$52,768,000
-24.4%
800,000
-40.7%
7.55%
-7.7%
IDYA SellIDEAYA BIOSCIENCES INC$49,428,000
-30.2%
3,600,000
-7.7%
7.07%
-14.8%
CYTK SellCYTOKINETICS INC$43,987,500
-36.0%
1,250,000
-16.7%
6.30%
-21.8%
IMVT SellIMMUNOVANT INC$38,775,000
-30.7%
2,500,000
-20.6%
5.55%
-15.3%
ISEE BuyIVERIC BIO INC$36,981,600
+15.2%
1,520,000
+1.3%
5.29%
+40.7%
XENE  XENON PHARMACEUTICALS INC$32,211,000
-9.2%
900,0000.0%4.61%
+10.9%
SRPT  SAREPTA THERAPEUTICS INC$30,322,600
+6.4%
220,0000.0%4.34%
+29.9%
BIIB NewBIOGEN INC$27,803,000100,000
+100.0%
3.98%
IMCR  IMMUNOCORE HLDGS PLCads$24,720,000
-13.4%
500,0000.0%3.54%
+5.8%
ALLK BuyALLAKOS INC$24,638,164
-44.7%
5,536,666
+4.7%
3.53%
-32.4%
VRDN SellVIRIDIAN THERAPEUTICS INC$24,168,000
-17.3%
950,000
-5.0%
3.46%
+1.1%
NBIX NewNEUROCRINE BIOSCIENCES INC$20,244,000200,000
+100.0%
2.90%
DYN SellDYNE THERAPEUTICS INC$19,584,000
-21.4%
1,700,000
-20.9%
2.80%
-4.0%
KRTX SellKARUNA THERAPEUTICS INC$18,164,000
-38.4%
100,000
-33.3%
2.60%
-24.7%
DSGN  DESIGN THERAPEUTICS INC$16,141,581
-43.8%
2,797,5010.0%2.31%
-31.3%
ASND NewASCENDIS PHARMA A/Ssponsored adr$16,083,000150,000
+100.0%
2.30%
BCYC SellBICYCLE THERAPEUTICS PLCsponsored ads$15,952,500
-62.4%
750,000
-47.7%
2.28%
-54.1%
RCKT BuyROCKET PHARMACEUTICALS INC$15,417,000
+5.0%
900,000
+20.0%
2.21%
+28.4%
AKRO  AKERO THERAPEUTICS INC$15,304,000
-30.2%
400,0000.0%2.19%
-14.7%
BMRN NewBIOMARIN PHARMACEUTICAL INC$14,586,000150,000
+100.0%
2.09%
BuyASTRIA THERAPEUTICS INC$13,897,968
+7.9%
1,044,960
+20.8%
1.99%
+31.8%
GLPG NewGALAPAGOS NVspon adr$13,524,000350,000
+100.0%
1.94%
OLMA  OLEMA PHARMACEUTICALS INC$12,991,246
+41.6%
3,743,8750.0%1.86%
+72.9%
MDGL SellMADRIGAL PHARMACEUTICALS INC$12,113,000
-30.4%
50,000
-16.7%
1.73%
-15.0%
SellDICE THERAPEUTICS INC$11,746,500
-43.0%
410,000
-37.9%
1.68%
-30.3%
NewDISC MEDICINE INC$11,124,750525,000
+100.0%
1.59%
COGT SellCOGENT BIOSCIENCES INC$10,790,000
-15.1%
1,000,000
-9.1%
1.54%
+3.6%
NewBIOHAVEN LTD$9,562,000700,000
+100.0%
1.37%
SellVENTYX BIOSCIENCES INC$9,045,000
-58.0%
270,000
-58.9%
1.30%
-48.7%
NewENLIVEN THERAPEUTICS INC$8,786,915401,229
+100.0%
1.26%
NewSTRUCTURE THERAPEUTICS INCsponsored ads$8,326,500350,000
+100.0%
1.19%
GERN SellGERON CORP$7,703,500
-20.4%
3,550,000
-11.2%
1.10%
-2.7%
ALXO SellALX ONCOLOGY HLDGS INC$6,780,000
-74.4%
1,500,000
-36.2%
0.97%
-68.7%
MOR BuyMORPHOSYS AGsponsored ads$5,940,000
+84.4%
1,500,000
+66.7%
0.85%
+125.5%
FGEN SellFIBROGEN INC$5,598,000
-33.4%
300,000
-42.9%
0.80%
-18.7%
NewMINERALYS THERAPEUTICS INC$4,698,000300,000
+100.0%
0.67%
CBAY SellCYMABAY THERAPEUTICS INC$3,488,000
-55.5%
400,000
-68.0%
0.50%
-45.6%
 VIGIL NEUROSCIENCE INC$1,844,338
-21.7%
188,3900.0%0.26%
-4.3%
SellTYRA BIOSCIENCES INC$1,408,905
+67.2%
87,673
-20.9%
0.20%
+104.0%
ALGS NewALIGOS THERAPEUTICS INC$874,0001,000,000
+100.0%
0.12%
IMUX NewIMMUNIC INC$627,564421,184
+100.0%
0.09%
 LIANBIOsponsored ads$548,800
+19.5%
280,0000.0%0.08%
+46.3%
NUVBWS  NUVATION BIO INC*w exp 07/07/202$8,000
-17.0%
66,6660.0%0.00%0.0%
SPRB ExitSPRUCE BIOSCIENCES INC$0-1,000,000
-100.0%
-0.13%
RAPT ExitRAPT THERAPEUTICS INC$0-200,000
-100.0%
-0.46%
RXDX ExitPROMETHEUS BIOSCIENCES INC$0-50,000
-100.0%
-0.64%
VERA ExitVERA THERAPEUTICS INCcl a$0-285,000
-100.0%
-0.65%
RETA ExitREATA PHARMACEUTICALS INCcl a$0-180,000
-100.0%
-0.80%
ANAB ExitANAPTYSBIO INC$0-250,000
-100.0%
-0.91%
CERE ExitCEREVEL THERAPEUTICS HLDNG I$0-260,000
-100.0%
-0.96%
FULC ExitFULCRUM THERAPEUTICS INC$0-2,000,000
-100.0%
-1.71%
ARQT ExitARCUTIS BIOTHERAPEUTICS INC$0-1,400,000
-100.0%
-2.43%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
CYTOKINETICS INC14Q3 202312.6%
KARUNA THERAPEUTICS INC14Q3 20235.6%
ALX ONCOLOGY HLDGS INC13Q3 202323.3%
DYNE THERAPEUTICS INC13Q3 20234.9%
APELLIS PHARMACEUTICALS INC12Q3 202312.4%
OLEMA PHARMACEUTICALS INC12Q3 202315.4%
DESIGN THERAPEUTICS INC11Q3 20238.0%
NUVATION BIO INC11Q3 20230.0%
BICYCLE THERAPEUTICS PLC10Q2 20235.7%
IDEAYA BIOSCIENCES INC9Q3 20239.5%

View Logos Global Management LP's complete holdings history.

Latest significant ownerships (13-D/G)

View Logos Global Management LP's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-04-01
SC 13G2024-02-22
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
SC 13G2024-01-22
SC 13G2024-01-22
SC 13G2024-01-02

View Logos Global Management LP's complete filings history.

Compare quarters

Export Logos Global Management LP's holdings